Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q4 FY25 results · Jan–Mar 2025
Alivus Life Sciences reported revenue from operations of ₹649.54 crore (up 21.0% from Q4 FY24) and net profit of ₹141.87 crore (up 44.9% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a standalone basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 649.54 | 536.60 | +21.0% | 641.84 | +1.2% |
| Other income | 10.09 | 3.13 | +222.2% | 10.46 | −3.5% |
| Total income | 659.63 | 539.73 | +22.2% | 652.30 | +1.1% |
| Profit before tax | 191.29 | 129.68 | +47.5% | 185.15 | +3.3% |
| Net profit for the period | 141.87 | 97.94 | +44.9% | 136.96 | +3.6% |
| EPS, basic (₹) | 11.57 | 7.99 | +44.8% | 11.18 | +3.5% |
| Net margin (%) | 21.8 | 18.3 | 21.3 |
Standalone
- Filed with BSE
- 15 May 2025, 21:43 IST
- Board meeting
- 15 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE